---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-090888"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T13:40:47.225837+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Armata appoints Dr. Deborah Birx as CEO, secures $25M credit from Innoviva

## Summary
- Dr. Deborah L. Birx appointed CEO and Board member; former Innoviva Board member and world-renowned healthcare leader.
- New $25M credit agreement with Innoviva; existing convertible credit maturity extended to Jan 10, 2025.
- Q2 loss from operations $(9.6)M; cash $12.5M at June 30, 2023; 36.1M shares outstanding.
- Phase 2 inhaled AP-PA02 in NCFB enrolling; AP-SA02 bacteremia study advancing to Phase 2a in 3Q23.
- $16.3M total grant funding from DoD/MTEC for AP-SA02 program.

## SEC filing metadata
- accession: 0001104659-23-090888
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465923090888/0001104659-23-090888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465923090888/tm2323624d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-090888
- JSON: https://secwatch.observer/filing/0001104659-23-090888.json
- Plain text: https://secwatch.observer/filing/0001104659-23-090888.txt

## Key facts
- Earnings Releases
  Armata Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: announced its financial results for the quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465923090888/0001104659-23-090888-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.